During the year the principal activity of the Company was the research, development and marketing of rapid testing technologies for infectious disease in humans and animals. The company’s core specialisation is the development of rapid testing diagnostics.
 |
 |
 |
- Shareholder Letter
- Chairman’s Message
- Board of Directors
- Managing Directors’ Review of Operations
- Executive Team
- Patent / Trademark Status
- Directors' Report
- » Directors
- » Principle Activites
- » Review of Operations
- » Financial Performance
- » Changes in State of Affairs
- » Subsequent Events
- » Future Development
- » Dividends
- » Share Options
- » Indemnifaction of Officers and Auditors
- » Directors' Meeting
- » Directors' Shareholdings
- » Remuneration Report
- » Proceedings on behalf of the Company
- » Non-Audit Services
- » Auditor's Independence Declaration
- Corpoate Governance Report
- Auditor’s Independant Declaration
- Independent Audit report
- Directors’ Declaration
- Statement of Financial Performance
- Statement of Cash Flows
- Statement of Changes in Equity
- Notes to the Financial Statements
- Additional ASX Information
Principle Activites
